Drug Discovery World

OCTOBER 13, 2022

There was a selection of the technologies we will present including cell-based assays, ion indicator dyes, inhibitors, pharmacokinetic assays, bioisimilars, assay development antibodies, conjugation particles and other reagents for your drug discovery and development pipeline. . Looking forward .

Drugs 52

Drugs In-Vivo In-Vitro Biobanking 52

The Pharma Data

OCTOBER 19, 2020

DB ( Becton, Dickinson and Company ) received a CE mark for its BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes for assessing immune function in COVID-19 patients. In a challenge trial, people are given a vaccine then intentionally dosed with the virus or bacteria that causes the disease. Please read more here. .

Vaccination 52

Vaccination Vaccine Trials Clinical Trials 52

Drug Discovery World

NOVEMBER 28, 2023

Scientists at the University of Bath have developed a way of joining up the head and tail of a protein, making it more stable and easier to get into cells. Drug treatments often work by binding to proteins involved in disease and blocking their activity, which either reduces symptoms or treats the disease.

Protein 59

Protein Drugs Reagent Life Science 59

Roots Analysis

OCTOBER 16, 2023

Once isolated, molecular clones can be used to generate multiple copies of DNA for the analysis of gene sequences and / or to express proteins obtained for the study or utilization of protein function. These clones can be manipulated and mutated in vitro to alter the expression and function of a protein.

DNA 40

DNA Gene Protein In-Vitro 40

Drug Discovery World

JULY 18, 2023

Current research is focused on designing CRISPR-enhanced CAR T cells that are resistant to immunosuppressive cytokines such as transforming growth factor-β (TGF-β) 2 , programmed cell death protein (PD-1) 3 , or other negative T cell regulators 4 (CTLA-4, LAG-3, and TIM-3), thus improving anti-tumour functions.

DNA 98

DNA Genome Genomics RNA 98

The Pharma Data

OCTOBER 14, 2020

The highly potent and selective payload series represents a powerful new class within ADC development with novel protein alkylating cytotoxicity. Under the terms of the non-exclusive agreement FASMAC acquires the right to use CRISPR/Cas9 technology and commercialize tools and reagents associated with it.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52